ITMCTR2200006741
Not yet recruiting
未知
Refractory advanced colorectal cancer in the treatment with integrated traditional Chinese and western medicine: a multi-center clinical study
onghua Hospital, Shanghai University of Traditional Chinese Medicine0 sitesTBD
Conditionscolorectal cancer
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- colorectal cancer
- Sponsor
- onghua Hospital, Shanghai University of Traditional Chinese Medicine
- Status
- Not yet recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Stage IV disease and histologically confirmed adenocarcinoma of the colon or rectum;
- •2\.Measurable index lesion according to RECIST1\.1 criteria;
- •3\.Age \=18 years old;
- •4\.RAS mutation (including KRAS, NRAS and HRAS)
- •5\.Organ function must meet the following requirements: (a) Blood routine: white blood cell count \=3×109/L, neutrophil count \=1\.5×109/L, hemoglobin \=90g/L, platelet count \= 75× 109/L. (b) Liver function: total bilirubin \=1\.5×ULN, ALT and AST\=2\.5×ULN (liver metastasis \=5×ULN). (c) Renal function: creatinine \=1\.5×ULN, creatinine clearance rate \> 50 mL/min. (d) Coagulation function: prothrombin time \=1\.5×ULN, activated partial thromboplastin time \=1\.5×ULN, international standardized ratio \=1\.5×ULN. (e) Electrolyte: serum magnesium and serum potassium \=LLN, allowing electrolyte correction during screening;
- •6\.Patients who intend to receive first\-line treatment or withdrawal from first\-line chemotherapy (regardless of containing molecular\-targeted drugs) for metastatic colorectal cancer due to intolerable toxicity or progressive disease, or relapse within 180 days after the last dose of adjuvant chemotherapy;
- •7\.Patients who are assessed as spleen deficiency syndrome;
- •8\.Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
- •9\.Estimated life expectancy \>3 months;
- •10\. Patients have informed consent and can cooperate with long\-term follow\-up.
Exclusion Criteria
- •1\.Other histological types of colorectal cancer except adenocarcinoma;
- •2\.RAS wild type status (including KRAS, HRAS and NRAS);
- •3\.Intestinal obstruction (except for patients who were relieved by fistulation or implantation stent) and active inflammatory bowel disease (patients who need medical intervention or have symptoms currently) before the study;
- •4\.Pregnant or breast feeding women; man or woman of child\-bearing potential not consenting to use adequate contraceptive methods or abstinence during the course of the study;
- •5\.Patients with mental disorders who cannot cooperate with treatment and follow\-up;
- •6\.Clinically significant cardiovascular diseases, such as cerebrovascular accident, myocardial infarction and unstable angina pectoris, New York Heart Association (NYHA) grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication (within 6 months before the study);
- •7\.Uncontrollable hypertension;
- •8\.High\-dose aspirin (\> 325mg/d) in a long term;
- •9\.Bleeding tendency or severe coagulation dysfunction;
- •10\.Inability to take drugs orally, lack of physical integrity of the upper gastrointestinal tract, malabsorption syndrome and other diseases that the doctor thinks may interfere with gastrointestinal movement or absorption;
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Treatment of Recurrent and Advance Colorectal Cancer (TRACC): A prospective multi-site registryAdvanced Colorectal CancerACTRN12618000404224Biogrid3,000
Active, not recruiting
Phase 1
A study for people with advanced colorectal cancer who have been treated with a specific chemotherapy regimen (Bevacizumab, Oxaliplatin, and a Fluoropyrimidine) which was ineffective in stopping the spread of the colorectal cancer. Study participants will receive a different chemotherapy regimen (Irinotecan, Folinic Acid, and 5-Fluorouracil) and be randomly and unknowingly assigned to also receive the study drug (ramucirimab) or a non-active compound (placebo).Metastatic Colorectal CancerMedDRA version: 17.0Level: LLTClassification code 10010036Term: Colorectal carcinomaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2010-021037-32-DEEli Lilly and Company Limited, Indianapolis1,050
Active, not recruiting
Not Applicable
Treatment Monitoring of Advanced Colorectal cancer with 18F-FDG PET/CTEUCTR2008-001499-55-FITurku PET Centre140
Completed
Not Applicable
Colomid: Midkine as a predictive marker in colorectal cancerACTRN12613000111774Calvary Mater Newcastle Hospital33
Not yet recruiting
Not Applicable
oCAlly advanced and recurrent Rectal cancer NAVigationAL Surgery – A Pilot Study (CARNAVAL)ocally advanced and recurrent rectal cancerNL-OMON28183ot applicable5